title: Effect of treatment on mononuclear cell migration in cervical cancer patients.
abstract: OBJECTIVE
  Our aim was to evaluate the effect of treatment on the in vitro migration of circulating mononuclear cells in cervical cancer patients at different stages.
  
  
  METHODS
  We prospectively investigated 24 patients with cervical neoplasia, without prior treatment, submitted to surgery or chemotherapy as therapeutic conduct. Controls were healthy volunteer women (n = 23). Mononuclear cells were isolated from peripheral venous blood before and after treatment, and their migration capacity was evaluated in a microchemotaxis chamber assay towards the chemotactic stimuli fMLP, MCP-1 and RANTES, compared to basal migration. Serum levels of nitric oxide metabolites were assayed by the Griess reaction.
  
  
  RESULTS
  Increased mononuclear cell migration in response to the chemotactic stimuli, compared to basal migration, was observed in controls and patients, without differences between them. After treatment (n = 14), mononuclear cell migration in response to MCP-1 and RANTES was increased compared to pre-treatment. Serum levels of nitric oxide metabolites were more elevated in patients (n = 19) than in controls (n = 17), but decreased after treatment (n = 15).
  
  
  CONCLUSIONS
  The results suggest that the production of soluble circulating factors by tumor cells could interfere with the functional activity of blood mononuclear cells.
authors.affiliation: Department of Biological Sciences, Federal University of Triângulo Mineiro, Uberaba, MG, Brazil.
authors.forename: Cristiana Bernadelli
authors.initials: CB
authors.lastname: Garcia
authors.forename: Paulo Cesar Júnior
authors.initials: PC
authors.lastname: Fernandes
authors.forename: Douglas Côbo
authors.initials: DC
authors.lastname: Micheli
authors.forename: Ana Helena Macedo
authors.initials: AH
authors.lastname: Pereira
authors.forename: Eddie Fernando Candido
authors.initials: EF
authors.lastname: Murta
authors.forename: Beatriz Martins
authors.initials: BM
authors.lastname: Tavares-Murta
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D016022:Case-Control Studies; D002465:Cell Movement / Q000187:drug effects; D018932:Chemokine CCL2 / Q000187:drug effects; D018946:Chemokine CCL5 / Q000187:drug effects; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D005260:Female; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000187:drug effects*; D008875:Middle Aged; D009569:Nitric Oxide / Q000097:blood / Q000378:metabolism; D011446:Prospective Studies; D044042:Receptors, Formyl Peptide / Q000187:drug effects; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology* / Q000601:surgery / Q000628:therapy*
chemical_list: C111835:CCL2 protein, human; D018932:Chemokine CCL2; D018946:Chemokine CCL5; D044042:Receptors, Formyl Peptide; D009569:Nitric Oxide